DDInter1289 DDInter1840
An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and pellagra. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake.
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Nicotinamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Carbamazepine
Carbamazepine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Trabectedin
Nicotinamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nateglinide
Nateglinide {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Trabectedin
Nicotinamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canagliflozin
Canagliflozin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Trabectedin
Nicotinamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canagliflozin
Canagliflozin {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Nicotinamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Carbamazepine
Carbamazepine {u} (Compound) causes {v} (Side Effect) Pulmonary embolism
Pulmonary embolism {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Nicotinamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glimepiride
Glimepiride {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Alanine aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Nicotinamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metformin
Metformin {u} (Compound) upregulates {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Nicotinamide {u} may lead to a major life threatening interaction when taken with {v} Lomitapide
Lomitapide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Trabectedin
Nicotinamide {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Leflunomide {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Trabectedin
Nicotinamide {u} may lead to a major life threatening interaction when taken with {v} Lomitapide
Lomitapide {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Alanine aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Nicotinamide may cause a minor interaction that can limit clinical effects when taken with Carbamazepine and Carbamazepine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Trabectedin (Compound)
Nicotinamide may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Trabectedin (Compound)
Nicotinamide may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Trabectedin (Compound)
Nicotinamide may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Trabectedin (Compound)
Nicotinamide may cause a minor interaction that can limit clinical effects when taken with Carbamazepine and Carbamazepine (Compound) causes Pulmonary embolism (Side Effect) and Pulmonary embolism (Side Effect) is caused by Trabectedin (Compound)
Nicotinamide may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Trabectedin (Compound)
Nicotinamide may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin (Compound) upregulates SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Nicotinamide may lead to a major life threatening interaction when taken with Lomitapide and Lomitapide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Trabectedin (Compound)
Nicotinamide may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Trabectedin (Compound)
Nicotinamide may lead to a major life threatening interaction when taken with Lomitapide and Lomitapide (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Trabectedin (Compound)